The challenges of biomarkers and diagnostics in drug development

Share Article

SMi’s 6th annual Biomarkers Summit held on 16th & 17th January in London will draw on advances in genomics, translational medicine and clinical trial design. It will bring you the latest developments from toxicity testing to compound screening and first-in-man studies to companion diagnostic assays, stay competitive with fresh insights from companies at the cutting edge of biopharmaceutical development.

News Image

SMi is pleased to confirm Adam Platt, Diagnostic Development Director, AstraZeneca as a speaker at the upcoming event.

He will speak on the utility of biomarkers to aid drug development and identifying patient subpopulations and applying to clinical development. It will also be interesting to hear his take on adapting development strategies to deliver companion diagnostics.

This event brings you examples of best practice in basic, pre-clinical, translational and clinical research. Whether utilising pharmacogenetics to aid clinical trial design or developing molecular diagnostics to aid patient stratification, attending this event will enable you to:

  •     Accelerate companion diagnostics development for therapeutic indications
  •     Validate and deliver biomarkers for patient selection during clinical trials
  •     Implement sub-grouping in patient segmentation studies
  •     Utilise revised FDA regulatory guidelines to aid product development
  •     Optimise reimbursement strategies for diagnostics
  •     Maximise biomarker identification using epigenetic and metabolomic insights

For more information visit alternatively contact Farhaana Rahman on +44 0 207 827 6186 or email on frahman(at)smi-online(dot)

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sonal Patel
SMi Group Ltd
0207 827 6106
Email >
Follow us on
Visit website